S
3.74
-0.08 (-2.09%)
| Previous Close | 3.82 |
| Open | 3.85 |
| Volume | 908,146 |
| Avg. Volume (3M) | 1,135,112 |
| Market Cap | 615,607,680 |
| Price / Book | 5.19 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2024 - 11 Nov 2024 |
| Diluted EPS (TTM) | -0.370 |
| Total Debt/Equity (MRQ) | 21.97% |
| Current Ratio (MRQ) | 14.90 |
| Return on Assets (TTM) | -30.22% |
| Return on Equity (TTM) | -58.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Savara, Inc. | Mixed | Bullish |
Stockmoo Score
0.9
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.88 |
|
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.73% |
| % Held by Institutions | 70.25% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (HC Wainwright & Co., 167.38%) | Buy |
| Median | 9.50 (154.01%) | |
| Low | 9.00 (JMP Securities, 140.64%) | Buy |
| Average | 9.50 (154.01%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 08 Oct 2024 | 10.00 (167.38%) | Buy | 3.78 |
| 01 Oct 2024 | 10.00 (167.38%) | Buy | 3.99 | |
| JMP Securities | 01 Oct 2024 | 9.00 (140.64%) | Buy | 3.99 |
| 09 Sep 2024 | 9.00 (140.64%) | Buy | 4.26 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |